We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Background:Pertuzumab plus trastuzumab provides a more comprehensive blockade of HER2 signalling than trastuzumab alone. Therefore, we conducted a phase IIa study of the pharmacokinetics and safety of pertuzumab plus trastuzumab and chemotherapy in advanced gastric cancer (aGC).Methods:Patients received pertuzumab 840 mg for cycle 1 and 420 mg q3w for(More)
  • 1